Southwest Oncology Group S0826: A phase 2 trial of SCH 727965 (NSC 727135, dinaciclib) in patients with stage IV melanoma

By sjmartinez • September 29, 2024

Lao CD, Moon J, Ma VT, Fruehauf JP, Flaherty LE, Bury MJ, Martin WG, Gross H, Akerley W, Hopkins JO, Patel SP, Sondak VK, Ribas A. Southwest Oncology Group S0826: A phase 2 trial of SCH 727965 (NSC 727135, dinaciclib) in patients with stage IV melanoma. Cancer. 2024 Sep 29. doi: 10.1002/cncr.35587. Epub ahead of print. PMID: 39342463.

Tags: CDK, CDK inhibition, cyclin‐dependent kinase, dinaciclib, Hematology/Oncology, melanoma, Publications

Access to AlloTx for AML: the value of the social phenotype

Schiller G. Access to AlloTx for AML: the value of the social phenotype. Blood. 2025 Jun 19;145(25):2941-2942. doi: 10.1182/blood.2025028826. PMID: 40536784.

Life Expectancy of American Indian and Alaska Native Persons and Underreporting of Mortality in Vital Statistics

Bor J, Bird M, Hakes JK, Himmelstein DU, Himmelstein G, Woolhandler S. Life Expectancy of American Indian and Alaska Native Persons and Underreporting of Mortality[...]

Primary Cardiac Diffuse Large B-Cell Lymphoma Managed With Rituximab, Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (R-EPOCH): A Case Report and Literature Review

Tai JW, Roufeh EN, Reed JP. Primary Cardiac Diffuse Large B-Cell Lymphoma Managed With Rituximab, Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (R-EPOCH): A Case Report[...]